Small Lymphocytic Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 46 expanded access programs, clinical trials, and compassionate use pathways listed for Small Lymphocytic Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with small lymphocytic lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 23 programs are currently active or recruiting, with the remaining 23 in other lifecycle stages. Sponsors actively running programs in this area include Loxo Oncology, Inc., National Cancer Institute (NCI), BeiGene, M.D. Anderson Cancer Center, Mayo Clinic, and others.
By recruiting status
Snapshot of where every Small Lymphocytic Lymphoma program currently sits in its lifecycle.
- Active / Recruiting23
- Inactive23
Top sponsors
Organisations running the most Small Lymphocytic Lymphoma programs in the directory.
- Loxo Oncology, Inc.4 programs
- National Cancer Institute (NCI)4 programs
- BeiGene3 programs
- M.D. Anderson Cancer Center3 programs
- Mayo Clinic3 programs
- Zulfa Omer3 programs
- City of Hope Medical Center2 programs
- Inhye Ahn2 programs
- Janssen Research & Development, LLC2 programs
- Masonic Cancer Center, University of Minnesota2 programs
Small Lymphocytic Lymphoma programs (46)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Long-term Study of Ibrutinib for Ongoing Access and Safety Monitoring — Janssen Research & Development, LLC
- Phase II Study of Ibrutinib and Short-Course Fludarabine for Untreated Chronic Lymphocytic Leukemia (CLL) — National Heart, Lung, and Blood Institute (NHLBI)
- Study on Bruton Tyrosine Kinase Inhibitor with or without Venetoclax for Veterans with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — VA Office of Research and Development
- Study Comparing Zanubrutinib with Bendamustine and Rituximab for Untreated CLL or SLL — BeiGene
- Study on the Effectiveness and Safety of Pirtobrutinib for Patients with Relapsed or Hard-to-Treat Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Loxo Oncology, Inc.
- Study on Nemtabrutinib for Patients with Difficult-to-Treat Blood Cancers — ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Study Comparing Pirtobrutinib (LOXO-305) and Bendamustine Plus Rituximab for Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) — Loxo Oncology, Inc.
- Study Comparing Pirtobrutinib (LOXO-305) and Ibrutinib for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) — Loxo Oncology, Inc.
- Study on Limiting Treatment Time with Acalabrutinib and Obinutuzumab for People with CLL or SLL — Memorial Sloan Kettering Cancer Center
- Study to Personalize Ibrutinib Treatment for Patients with Untreated Chronic Lymphocytic Leukemia — Janssen Research & Development, LLC
- Study on the Safety and Effectiveness of BGB-16673 Compared to Pirtobrutinib in Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — BeOne Medicines
- Study on Sonrotoclax with Obinutuzumab or Rituximab Compared to Venetoclax with Rituximab for Treating Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — BeiGene
- Study on Acalabrutinib, Umbralisib, and Ublituximab for Relapsed and Untreated Chronic Lymphocytic Leukemia (CLL) — Jennifer R. Brown, MD, PhD
- Study on Acalabrutinib for Treating Chronic Lymphocytic Leukemia, Richter's Syndrome, or Prolymphocytic Leukemia — Acerta Pharma BV
- Study Comparing Ibrutinib and Rituximab with Fludarabine, Cyclophosphamide, and Rituximab for Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — National Cancer Institute (NCI)
- Study Comparing Intermittent and Continuous Venetoclax with Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Zulfa Omer
- Study on Lenalidomide and Vaccine Therapy for Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — National Cancer Institute (NCI)
- Study on LP-168 and Obinutuzumab for Treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Its Variants — Zulfa Omer
- Study on Mosunetuzumab for Clearing Minimal Residual Disease in Chronic Lymphocytic Leukemia (CLL) — Inhye Ahn
- Study on Sonrotoclax, Rituximab, and Zanubrutinib for Treating Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma — Fred Hutchinson Cancer Center
- Study on Epcoritamab as a Follow-Up Treatment for CLL/SLL — Zulfa Omer
- Testing the Addition of Venetoclax to Standard Treatment for Older Patients with Untreated Chronic Lymphocytic Leukemia — National Cancer Institute (NCI)
- Study on Venetoclax and Obinutuzumab Followed by Epcoritamab for Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma — City of Hope Medical Center
- Study on BGB-16673 for Patients with B-Cell Blood Cancers — BeiGene
- Study Comparing Nemtabrutinib with Ibrutinib or Acalabrutinib for First-Time Treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) — Merck Sharp & Dohme LLC
- Study on Using Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adults with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — AstraZeneca
- Study Comparing Pirtobrutinib with Venetoclax and Rituximab to Venetoclax and Rituximab Alone in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Loxo Oncology, Inc.
- Study on Acalabrutinib and Obinutuzumab for Treating Chronic Lymphocytic Leukemia — M.D. Anderson Cancer Center
- Study on Acalabrutinib Combined with Venetoclax or Obinutuzumab for Untreated Chronic Lymphocytic Leukemia — Ohio State University Comprehensive Cancer Center
- Study on Acalabrutinib With or Without Obinutuzumab for Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Mayo Clinic
- Study on Acalabrutinib, Venetoclax, and Durvalumab for Treating Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Mayo Clinic
- Study on Using Reduced Intensity Conditioning and Post-Transplant Cyclophosphamide for Blood Disorders — Masonic Cancer Center, University of Minnesota
- Study on Atezolizumab, Obinutuzumab, and Venetoclax for Treating Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed/Refractory Richter Syndrome — M.D. Anderson Cancer Center
- Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia — Inhye Ahn
- Study on Ibrutinib and Vaccine Therapy for Patients with Asymptomatic, High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Jennifer Woyach
- Study on Myeloablative Stem Cell Transplant with Donor for Blood Disorders — Masonic Cancer Center, University of Minnesota
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, Advanced DLBCL, ALL, and High-Risk LBCL — Novartis Pharmaceuticals
- Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi — Kerry Rogers
- Study on Pirtobrutinib (LOXO-305) and Venetoclax for Treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — M.D. Anderson Cancer Center
- Study on Pirtobrutinib and Venetoclax with MRD Detection for Untreated Chronic Lymphocytic Leukemia — Mayo Clinic
- Study on Reduced-Intensity Conditioning to Lower Treatment-Related Deaths in Patients Undergoing Stem Cell Transplant — Thomas Jefferson University
- Study on the Safety and Effectiveness of Epcoritamab for Treating Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome — Genmab
- Study of Iopofosine I 131 (CLR 131) for Certain B-Cell Blood Cancers and Waldenstrom Macroglobulinemia — Cellectar Biosciences, Inc.
- Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study — City of Hope Medical Center
- Testing Early Treatment for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study — National Cancer Institute (NCI)
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL — Massachusetts General Hospital
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Small Lymphocytic Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.